Literature DB >> 27221883

Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.

Ahoua B Effi1, N'guiessan A Aman, Baumaney S Koui, Kouadio D Koffi, Zie C Traore, Mohamed Kouyate.   

Abstract

BACKGROUND: Breast cancer is a heterogeneous disease that represents a major public health problem. The immunohistochemical determination of breast cancer subtypes with regard to estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2) status can contribute to improved selection of therapy and patientcare. The purpose of this study was to determine the prevalence of the molecular breast cancer subtypes and to assess their associations with classical clinicopathologic parameters for better therapeutic decisions in women with breast cancer in the Ivory Coast.
MATERIALS AND METHODS: Formalin- fixed and paraffin-embedded blocks of patients diagnosed with primary breast carcinoma were subjected to immunohistochemical assay for the assessment of ER/RP and HER2 expression. The one-way analysis of variance evaluated the difference between breast cancer subtypes and mean age of patients. The Chi-square Test was used to compare standard clinicopathologic prognostic parameters with tumor subtypes.
RESULTS: Among 302 patients, 57% were premenopausal and 43% were postmenopausal. The invasive ductal carcinoma not otherwise specified (IDC NOS) (82.8%) was the most frequent histological type, and the tumor grade 2 (56%) was predominant followed by grade 3 (20.9%). The proportion of positivity of ER, PR, and HER2 was 56%, 49%, and 15.6%, respectively. Half of patients of this study (51.6%) had luminal A breast tumor type followed by TN (32.1%). Other subtypes were luminal B (10.1% ) and non-luminal HER2+ (6.3%).
CONCLUSIONS: The findings of the present study are in line with the literature and should assist in management of breast cancer in our country.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27221883     DOI: 10.7314/apjcp.2016.17.4.1973

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  6 in total

1.  The prognostic value of quantitative analysis of CCL5 and collagen IV in luminal B (HER2-) subtype breast cancer by quantum-dot-based molecular imaging.

Authors:  Yong-Yun Zhu; Chuang Chen; Juan-Juan Li; Sheng-Rong Sun
Journal:  Int J Nanomedicine       Date:  2018-06-28

2.  Pathology of Senegalese breast cancers.

Authors:  Megan Burke Fitzpatrick; Mara Hester Rendi; Nancy Barbara Kiviat; Pape Toure; Amadou Dem; Papa Salif Sow; Stephen Edward Hawes; Qinghua Feng; Kimberly Heller Allison
Journal:  Pan Afr Med J       Date:  2019-10-02

3.  Breast cancer in togolese women: immunohistochemistry subtypes.

Authors:  Ablavi Adani-Ifè; Koffi Amégbor; Kwamé Doh; Tchin Darré
Journal:  BMC Womens Health       Date:  2020-11-23       Impact factor: 2.809

4.  The distribution of reproductive risk factors disclosed the heterogeneity of receptor-defined breast cancer subtypes among Tanzanian women.

Authors:  Linus P Rweyemamu; Gokce Akan; Ismael C Adolf; Erick P Magorosa; Innocent J Mosha; Nazima Dharsee; Lucy A Namkinga; Sylvester L Lyantagaye; Abdolrahman S Nateri; Fatmahan Atalar
Journal:  BMC Womens Health       Date:  2021-12-20       Impact factor: 2.809

5.  Immunohistochemical Features of Breast Cancer Seen in Women in Kinshasa, Democratic Republic of the Congo: A Six-Year Retrospective Study.

Authors:  Stanislas Maseb'a Mwang Sulu; Donatien Babaka Batalansi; Arnold Maseb Sul Sulu; Olivier Mukuku; Justin Esimo Mboloko; Désiré Kulimba Mashinda; Bienvenu Lebwaze Massamba; Antoine Wola Tshimpi
Journal:  Int J Breast Cancer       Date:  2022-08-05

6.  Novel Galiellalactone Analogues Can Target STAT3 Phosphorylation and Cause Apoptosis in Triple-Negative Breast Cancer.

Authors:  Hyejin Ko; Jong Hyun Lee; Hyun Su Kim; Taewoo Kim; Young Taek Han; Young-Ger Suh; Jaemoo Chun; Yeong Shik Kim; Kwang Seok Ahn
Journal:  Biomolecules       Date:  2019-05-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.